What’s new in 2019? Nowadays, the most significant impact on the Indian industry is anything that happens in the US, more so, since most Indian majors have more than 50% revenue dependence on that market. Trend 1: 2017-18 saw most of these companies build a very differentiated portfolio that included biosimilars, complex generics and differentiated […]Read More Will 2019 be more of the same for pharma?
Changes in pharma marketing will be profound with the advent of technology. Digital marketing will allow pharma marketers to engage the customer in very meaningful ways which were not always possible through the work of sales reps. While sales reps are important in the scheme of things, they are but one channel. In-clinic time with […]Read More Don’t make it feel like it’s marketing
Whether Amazon succeeds in the healthcare market, or not, remains to be seen, but the reason I believe healthcare is about to get ‘Amazonized’ is because of what Chris Holt, Amazon’s leader of Global Healthcare said recently. “When we think about the healthcare space, our overall philosophy of obsessing around the customer has served us […]Read More ‘Amazonization’ of Healthcare
In early June, the government think tank Niti Aayog unveiled its discussion paper on national strategy on Artifical Intelligence (AI) which aims to guide research and development in new and emerging technologies. While the paper per se focuses on five sectors for India — healthcare, agriculture, education, smart cities and infrastructure and transportation, this post will […]Read More India looks to Artificial Intelligence to solve Health Infra Problems
The first time I heard the term ‘digital economy’ in the medical context, it was from a reputed doctor who was a co-panelist and speaker at a company town hall event on digital marketing. It did not surprise me one bit that the doctor knew more about the digital economy than most of the pharma […]Read More The Digital Economy
Towards the end of March, GSK found itself becoming the top contender for Pfizer’s Consumer Business. There was much speculation of how GSK CEO Emma Walmsley would find the $20 billion that Pfizer had reportedly valued its business at. However, within 24-48 hours, not only did GSK back out of bidding at Pfizer’s auction, it […]Read More Is GSK shedding legacy to build its future?
The news broke with dawn today. An era had passed. And it passed as peacefully and privately as he would have probably wanted it to. Tarun Gupta – professor to youngsters, boss and mentor to those slightly older, but ‘Sir’ to almost everyone in the vast Indian pharmaceutical industry, was no more. As the sun […]Read More TG – An Era That Passed